Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Aaron Boster, Mary Pat Bartoszek, Colleen O'connell, David Pitt, Michael Racke

Résultat de recherche: Review articleexamen par les pairs

40 Citations (Scopus)

Résumé

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA) remains unique given its non-immunosuppressive mechanism of action as well as its superior long-term safety and sustained efficacy data. In this review, we discuss proposed mechanisms of action of GA. Then we review efficacy data for reduction of relapses and slowing disability as well as long term safety data. Finally we discuss possible future directions of this unique polymer in the treatment of MS.

Langue d'origineEnglish
Pages (de-à)319-332
Nombre de pages14
JournalTherapeutic Advances in Neurological Disorders
Volume4
Numéro de publication5
DOI
Statut de publicationPublished - sept. 2011
Publié à l'externeOui

Note bibliographique

Funding Information:
This work was supported by NINDS (grant number RO1 NS 037513 to MKR).

ASJC Scopus Subject Areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Empreinte numérique

Plonger dans les sujets de recherche 'Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis'. Ensemble, ils forment une empreinte numérique unique.

Citer